CO2019006565A2 - Novedoso conjugado de amanitina - Google Patents
Novedoso conjugado de amanitinaInfo
- Publication number
- CO2019006565A2 CO2019006565A2 CONC2019/0006565A CO2019006565A CO2019006565A2 CO 2019006565 A2 CO2019006565 A2 CO 2019006565A2 CO 2019006565 A CO2019006565 A CO 2019006565A CO 2019006565 A2 CO2019006565 A2 CO 2019006565A2
- Authority
- CO
- Colombia
- Prior art keywords
- conjugate
- novel
- amatoxin
- amino acid
- binding moiety
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
La invención se refiere a un conjugado que comprende (a) una amatoxina que comprende un aminoácido 4 con una posición 6'-desoxi; y (ii) un aminoácido 8 con una posición S-desoxi; (b) un resto de unión a BCMA que comprende (i) los dominios variables del anticuerpo humanizado J22.9-ISY, y (ii) una región constante de cadena pesada que comprende una mutación D265C; y (c) un enlazador escindible por la proteasa que enlaza dicha amatoxina y dicho resto de unión a diana. La invención se refiere además a una composición farmacéutica que comprende dicho conjugado, particularmente, para el uso en el tratamiento del mieloma múltiple.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16206849 | 2016-12-23 | ||
PCT/EP2017/084431 WO2018115466A1 (en) | 2016-12-23 | 2017-12-22 | Amanitin antibody conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2019006565A2 true CO2019006565A2 (es) | 2019-09-18 |
Family
ID=57680140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2019/0006565A CO2019006565A2 (es) | 2016-12-23 | 2019-06-20 | Novedoso conjugado de amanitina |
Country Status (14)
Country | Link |
---|---|
US (1) | US11446388B2 (es) |
EP (1) | EP3558390A1 (es) |
JP (1) | JP7038717B2 (es) |
KR (1) | KR102455175B1 (es) |
CN (1) | CN110099698B (es) |
AU (1) | AU2017380099A1 (es) |
BR (1) | BR112019012937A2 (es) |
CA (1) | CA3044508A1 (es) |
CL (1) | CL2019001740A1 (es) |
CO (1) | CO2019006565A2 (es) |
MX (1) | MX2019007604A (es) |
RU (1) | RU2755728C2 (es) |
WO (1) | WO2018115466A1 (es) |
ZA (1) | ZA201903062B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230082055A (ko) | 2016-06-17 | 2023-06-08 | 마젠타 테라퓨틱스 인코포레이티드 | 세포의 고갈을 위한 조성물 및 방법 |
JOP20190156B1 (ar) | 2016-12-23 | 2023-09-17 | Bayer Pharma AG | أميدات عطرية لحمض الكربوكسيليك بصفتها مضادات لمستقبلة البراديكينين b1 |
WO2018134787A2 (en) | 2017-01-20 | 2018-07-26 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd137+ cells |
AU2018317611B2 (en) * | 2017-08-18 | 2022-03-10 | Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Non-natural amatoxin-type antibody conjugate |
EP3773740A1 (en) * | 2018-04-13 | 2021-02-17 | Heidelberg Pharma Research GmbH | Targeted amatoxin conjugate for the treatment of solid tumors |
JP2022512629A (ja) * | 2018-10-23 | 2022-02-07 | マジェンタ セラピューティクス インコーポレイテッド | Fcサイレンス化抗体薬物コンジュゲート(ADC)及びその使用 |
JP2022530026A (ja) | 2019-04-24 | 2022-06-27 | ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング | アマトキシン抗体薬物複合体及びその使用 |
CN114144201A (zh) * | 2019-05-23 | 2022-03-04 | 海德堡医药研究有限责任公司 | 含可裂解连接基的抗体药物缀合物 |
AR120218A1 (es) * | 2019-10-15 | 2022-02-02 | Heidelberg Pharma Res Gmbh | Conjugados de amatoxina y anticuerpo específico de linfocitos b |
JP2023502745A (ja) * | 2019-11-21 | 2023-01-25 | アンナチュラル・プロダクツ・インコーポレイテッド | 細胞透過性環状ペプチドおよびその使用 |
CA3195572A1 (en) | 2020-11-04 | 2022-05-12 | Heidelberg Pharma Research Gmbh | Composition comprising a combination of immune checkpoint inhibitor and antibody-amatoxin conjugate for use in cancer therapy |
WO2022187591A1 (en) | 2021-03-05 | 2022-09-09 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
AR125130A1 (es) | 2021-03-19 | 2023-06-14 | Heidelberg Pharma Res Gmbh | Conjugados de amatoxina y anticuerpo específicos de linfocitos b |
CA3228178A1 (en) | 2021-08-05 | 2023-02-09 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
WO2023194539A1 (en) | 2022-04-07 | 2023-10-12 | Heidelberg Pharma Research Gmbh | Methods of improving the therapeutic index of amatoxin-antibody conjugates |
CN114839284B (zh) * | 2022-04-14 | 2024-03-26 | 中国疾病预防控制中心职业卫生与中毒控制所 | 非疾病诊断目的的鹅膏毒肽检测方法 |
EP4353220A1 (en) | 2022-10-12 | 2024-04-17 | Pierre Fabre Medicament | Use of a liquid aqueous composition for solubilization and stabilization of an antibody-drug conjugate |
US20240165257A1 (en) | 2022-11-01 | 2024-05-23 | Heidelberg Pharma Research Gmbh | Anti-gucy2c antibody and uses thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
EP1859811B1 (en) * | 2006-05-27 | 2011-08-24 | Faulstich, Heinz, Dr. | Use of conjugates of amatoxins or phallotoxins with macromolecules for tumor and inflammation therapy |
JP2012523383A (ja) | 2009-04-08 | 2012-10-04 | ファウルシュティヒ,ハインツ | がんの治療のためのアマトキシンと複合体形成した標的結合部分 |
WO2010115629A2 (en) * | 2009-04-08 | 2010-10-14 | Deutsches Krebsforschungszentrum | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
CA2758230A1 (en) | 2009-04-09 | 2010-10-14 | Aqua Rehab Inc. | Device and method for sealing a junction between a main pipe and a lateral pipe connected thereto |
US20130028917A1 (en) | 2010-04-15 | 2013-01-31 | Spirogen Developments Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
EP2436398B1 (en) * | 2010-09-30 | 2013-01-23 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkers |
EP2497499A1 (en) | 2011-03-10 | 2012-09-12 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkages |
EP2684865A1 (en) | 2012-07-13 | 2014-01-15 | Heidelberg Pharma GmbH | Methods for synthesizing amatoxin building block and amatoxins |
EP3508503B1 (en) | 2012-11-01 | 2022-11-02 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Antibody against cd269 (bcma) |
US9243058B2 (en) * | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
EP2774624A1 (en) | 2013-03-04 | 2014-09-10 | Heidelberg Pharma GmbH | Amatoxin derivatives |
JP6321687B2 (ja) * | 2014-03-10 | 2018-05-09 | ハイデルベルク ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | アマトキシン誘導体 |
NZ725701A (en) | 2014-04-30 | 2023-09-29 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Humanized antibodies against cd269 (bcma) |
MX2017005268A (es) | 2014-10-24 | 2017-07-26 | Dupont Nutrition Biosci Aps | Tripeptidil peptidasas tolerantes a prolina y usos de las mismas. |
LT3268047T (lt) * | 2015-03-09 | 2023-11-10 | Heidelberg Pharma Research Gmbh | Amatoksino-antikūno konjugatai |
EP3222292A1 (en) * | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
MX2018015684A (es) | 2016-06-17 | 2019-08-29 | Magenta Therapeutics Inc | Composiciones y metodos para el agotamiento de celulas cd117. |
-
2017
- 2017-12-22 WO PCT/EP2017/084431 patent/WO2018115466A1/en active Search and Examination
- 2017-12-22 BR BR112019012937A patent/BR112019012937A2/pt unknown
- 2017-12-22 JP JP2019534106A patent/JP7038717B2/ja active Active
- 2017-12-22 MX MX2019007604A patent/MX2019007604A/es unknown
- 2017-12-22 US US16/470,950 patent/US11446388B2/en active Active
- 2017-12-22 EP EP17832077.6A patent/EP3558390A1/en active Pending
- 2017-12-22 KR KR1020197017338A patent/KR102455175B1/ko active IP Right Grant
- 2017-12-22 CA CA3044508A patent/CA3044508A1/en active Pending
- 2017-12-22 RU RU2019119442A patent/RU2755728C2/ru active
- 2017-12-22 CN CN201780079545.8A patent/CN110099698B/zh active Active
- 2017-12-22 AU AU2017380099A patent/AU2017380099A1/en active Pending
-
2019
- 2019-05-16 ZA ZA2019/03062A patent/ZA201903062B/en unknown
- 2019-06-20 CO CONC2019/0006565A patent/CO2019006565A2/es unknown
- 2019-06-20 CL CL2019001740A patent/CL2019001740A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20190328899A1 (en) | 2019-10-31 |
KR20190100190A (ko) | 2019-08-28 |
CN110099698B (zh) | 2023-02-17 |
ZA201903062B (en) | 2023-08-30 |
JP7038717B2 (ja) | 2022-03-18 |
MX2019007604A (es) | 2019-08-16 |
RU2019119442A3 (es) | 2021-03-04 |
JP2020504736A (ja) | 2020-02-13 |
CL2019001740A1 (es) | 2019-12-06 |
KR102455175B1 (ko) | 2022-10-17 |
US11446388B2 (en) | 2022-09-20 |
RU2755728C2 (ru) | 2021-09-20 |
BR112019012937A2 (pt) | 2019-12-10 |
WO2018115466A1 (en) | 2018-06-28 |
CN110099698A (zh) | 2019-08-06 |
AU2017380099A1 (en) | 2019-06-13 |
RU2019119442A (ru) | 2020-12-21 |
EP3558390A1 (en) | 2019-10-30 |
CA3044508A1 (en) | 2018-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019006565A2 (es) | Novedoso conjugado de amanitina | |
BR112019012354A2 (pt) | anticorpos apenas de cadeia pesada anti-bcma | |
CY1124834T1 (el) | Αναστολεις της αλληλεπιδρασης της μηνινης-mll | |
CY1123977T1 (el) | Anti-pd-1 και anti-lag3 αντισωματα για την θεραπεια του καρκινου | |
CL2020000263A1 (es) | Conjugado de anticuerpo monoclonal contra bcma-fármaco. | |
PE20181805A1 (es) | Composiciones y anticuerpos anti-tim-3 | |
PH12018501419A1 (en) | Pharmaceutical composition comprising bispecific antibody constructs | |
CL2023000895A1 (es) | Receptores quiméricos de dll3 y métodos para su uso | |
CO2017000754A2 (es) | Anticuerpo monoclonal anti-ctla4 o fragmento de unión a antígeno del mismo, y una composición farmacéutica del mismo | |
CO2018011195A2 (es) | Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4 | |
PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
CY1125025T1 (el) | 2-φορμυλ-3-υδροξυφαινυλοξυμεθυλ ενωσεις ικανες ρυθμισης αιμοσφαιρινης | |
CO2020010345A2 (es) | Dominios variables de anticuerpos que se dirigen al receptor nkg2d | |
PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
NZ734892A (en) | Amatoxin-antibody conjugates | |
AR117913A2 (es) | Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
CL2023002105A1 (es) | Dominios variables de anticuerpo que se dirigen a cd33 y sus usos | |
MX2022006461A (es) | Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos. | |
PE20210167A1 (es) | Proteinas de union multiespecificas y mejoras con estas | |
BR112021019334A2 (pt) | Anticorpos de cadeia pesada que se ligam ao psma | |
MX2020012679A (es) | Compuestos de amino-pirazincarboxamida, conjugados, y usos de los mismos. | |
BR112019000693A2 (pt) | composições de muc1- car e métodos para uso | |
EA202091161A1 (ru) | Конъюгаты антител против cd22 с майтанзином, их комбинации и способы применения | |
PE20201171A1 (es) | Anticuerpos de cadena pesada que se unen a cd22 | |
MX2022009915A (es) | Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos. |